Dexamethasone reduces the formation of thoracic aortic aneurysm and dissection in a murine model

Myofibrillogenesis Regulator-1 in Smooth Muscle Cells Modulates Inflammation Signaling Pathways via Regulating ROCK1 Ubiquitination and Degradation to Impact Aortic Dissection

Background

Aortic dissection (AD) is a life-threatening cardiovascular emergency and currently lacks effective drug treatment. Inflammation is a critical mechanism in the development of AD, and identifying specific molecular targets to regulate inflammation is crucial for stopping its progression. This study aimed to investigate the role of MR-1 and ROCK1 in the regulation of inflammation in AD and their potentialities as therapeutic targets.

Methods

Researchers performed protein immunoblotting on aortic wall tissue from 10 patients who underwent aortic arch replacement and 10 patients who underwent coronary artery bypass grafting to examine the expression levels of MR-1, ROCK1, and inflammatory pathways in the aortas. In vitro experiments, human aortic smooth muscle cells were extracted, and an in vitro dissection model was constructed with angiotensin II. siRNA silencing studies were performed to investigate the effects of MR-1 and ROCK1 on the development of AD and their interconnections.

Results

Analysis of aortic tissues revealed significantly elevated levels of MR-1 and ROCK1 in AD patients, and meanwhile the inflammatory indexes showed the same trend. Furthermore, it was observed that overexpression of MR-1 and ROCK1 facilitated smooth muscle cell phenotypic transformation and augmented matrix metalloproteinase release in in vitro settings through inflammatory pathway activation. The relationship between MR-1 and ROCK1 was elucidated, too.

Conclusion

MR-1 and ROCK1 overexpression is associated with the occurrence and development of AD through inflammation. This study highlights the role of inflammation in AD development and tap the potentiality of using MR-1 and ROCK1 as targets to alleviate AD development.

Animal Models, Pathogenesis, and Potential Treatment of Thoracic Aortic Aneurysm

Thoracic aortic aneurysm (TAA) has a prevalence of 0.16-0.34% and an incidence of 7.6 per 100,000 person-years, accounting for 1-2% of all deaths in Western countries. Currently, no effective pharmacological therapies have been identified to slow TAA development and prevent TAA rupture. Large TAAs are treated with open surgical repair and less invasive thoracic endovascular aortic repair, both of which have high perioperative mortality risk. Therefore, there is an urgent medical need to identify the cellular and molecular mechanisms underlying TAA development and rupture to develop new therapies. In this review, we summarize animal TAA models including recent developments in porcine and zebrafish models: porcine models can assess new therapeutic devices or intervention strategies in a large mammal and zebrafish models can employ large-scale small-molecule suppressor screening in microwells. The second part of the review covers current views of TAA pathogenesis, derived from recent studies using these animal models, with a focus on the roles of the transforming growth factor-beta (TGFβ) pathway and the vascular smooth muscle cell (VSMC)-elastin-contractile unit. The last part discusses TAA treatment options as they emerge from recent preclinical studies.

Bioinformatics Analysis Reveals Cell Cycle-Related Gene Upregulation in Ascending Aortic Tissues From Murine Models

Thoracic aortic aneurysm and dissection (TAAD) is a high-risk aortic disease. Mouse models are usually used to explore the pathological progression of TAAD. In our studies, we performed bioinformatics analysis on a microarray dataset (GSE36778) and verified experiments to define the integrated hub genes of TAAD in three different mouse models. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI) network analyses, and histological and quantitative reverse transcription-PCR (qRT-PCR) experiments were used in our study. First, differentially expressed genes (DEGs) were identified, and twelve common differentially expressed genes were found. Second, genes related to the cell cycle and inflammation were enriched by using GO and PPI. We focused on filtering and validating eighteen hub genes that were upregulated. Then, expression data from human ascending aortic tissues in the GSE153434 dataset were also used to verify our findings. These results indicated that cell cycle-related genes participate in the pathological mechanism of TAAD and provide new insight into the molecular mechanisms of TAAD.

Dexamethasone attenuated thoracic aortic aneurysm and dissection in vascular smooth muscle cell Tgfbr2 disrupted mice with CCL8 suppression

NEW FINDINGS

What is the central question of this study? The aim of this study was to investigate the relationship of CCL8 and the thoracic aortic aneurysm and dissection (TAAD) formation in postnatal mice with vascular smooth muscle cell (VSMC) Tgfbr2 disruption and whether dexamethasone could be a potential treatment. What is the main finding and its importance? CCL8 was associated with the formation of TAAD in VSMC Tgfbr2 disrupted mice. Dexamethasone reduced TAAD formation and inhibited MAPK (p-p38) and NF-κB (p-p65) signaling pathways. CCL8 might be an important promoter in aortic inflammation. DEX provided potential therapeutic effects in TAAD treatment.

ABSTRACT

Aortic inflammation plays a vital role in initiation and progression of thoracic aortic aneurysm and dissection (TAAD). The disturbance of transforming growth factor-β (TGF-β) signaling pathway is believed to be one of the pathogenic mechanisms of TAAD. Initially, Myh11-CreER^T2 .Tgfbr2^f/f male mice were used to build TAAD mice model. And bioinformatics analyses revealed the enriched inflammatory signal pathways and upregulated chemokine CCL8. So we hypothesized that vascular smooth muscle cell (VSMC) Tgfbr2 disruption in postnatal mice resulted in aortic inflammation associated with CCL8 secretion. Then real-time quantitative PCR and serum ELISA results confirmed that CCL8 expression began to increase after VSMC Tgfbr2 disruption. Next, we cultured mouse thoracic aortas ex vivo, and observed that the protein expressions of CCL8 in culture supernatants were increased by ELISA. Subsequently, the co-localization of CCL8 with α-smooth muscle actin (α-SMA) orCD68 was found significantly increased by immunofluorescence. Then, dexamethasone (DEX) was used to treat TAAD in VSMC Tgfbr2 disrupted mice The results of histochemical, immunofluorescence and immunohistochemical staining indicated that DEX therapy reduced CCL8 secretion, inflammatory cell recruitment, aortic medial thickening, elastic fiber fragmentating, extracellular matrix degradation, contractile apparatus impairment, thereby ameliorated TAAD formation. Western blot showed that MAPK and NF-κB signaling pathways in aorta were overactivated after VSMC Tgfbr2 disruption, but inhibited by DEX therapy. Altogether, CCL8 might be an important promoter in TAAD formation of VSMC Tgfbr2 disrupted mice. And DEX provided potential therapeutic effects in TAAD treatment. This article is protected by copyright. All rights reserved.

β-Aminopropionitrile-induced aortic aneurysm and dissection in mice

The mechanistic basis for the formation of aortic aneurysms and dissection needs to be elucidated to facilitate the development of effective medications. β-Aminopropionitrile administration in mice has been used frequently to study the pathologic features and mechanisms of aortic aneurysm and dissection. This mouse model mimics several facets of the pathology of human aortic aneurysms and dissection, although many variables exist in the experimental design and protocols that must be resolved to determine its application to the human disease. In the present brief review, we have introduced the development of this mouse model and provided insights into understanding its pathologic features.